Translational research has further revealed that treatment with IGF-1 significantly reduces left ventricular volume, attenuates left ventricular mass and improves stroke volume in STEMI patients (37), and improves EF in HF patients (38). The gene discussed is IGF1; the disease is hydrops fetalis.